key: cord-0997252-7knea0ke
authors: Bar-Meir, Maskit; Guri, Alex; Godfrey, Max E.; Shack, Avram R.; Hashkes, Philip J.; Goldzweig, Ofra; Megged, Orli
title: Characterizing the differences between multisystem inflammatory syndrome in children and Kawasaki disease
date: 2021-07-05
journal: Sci Rep
DOI: 10.1038/s41598-021-93389-0
sha: 2848184a9510f8d3d475a074ec08c32612996452
doc_id: 997252
cord_uid: 7knea0ke

To characterize the new SARS-Co-V-2 related multisystem inflammatory syndrome in children (MIS-C) among Israeli children and to compare it with Kawasaki disease (KD). We compared, in two medical centers, the clinical and laboratory characteristics of MIS-C, KD and an intermediate group, which met the case definitions of both conditions. MIS-C patients were older, were more likely to be hypotensive, to have significant gastrointestinal symptoms, lymphopenia and thrombocytopenia and to have non-coronary abnormal findings in their echocardiogram. Lymphopenia was an independent predictor of MIS-C. Most of our MIS-C patients responded promptly to corticosteroid therapy. KD incidence in both centers was similar in 2019 and 2020. Although there is clinical overlap between KD and MIS-C, these are separate entities. Lymphopenia clearly differentiates between these entities. MIS-C patients may benefit from corticosteroids as first-line therapy.

The first case of COVID-19 in Israel was recorded in February 21, 2020. We have collected data of all pediatric patients, meeting the CDC and/or WHO case definitions for MIS-C, who presented to two medical centers serving Jerusalem and the Southern plains of Israel. The Jerusalem area had the highest incidence of COVID-19 in the country 11 . In the Jerusalem medical center we also collected data of all patients who met the KD diagnostic algorithm 9 during the COVID-19 epidemic. SARS-Cov-2 RT-PCR on nasal swabs was performed for all febrile patients requiring admission. Serology was performed using a commercial kit, which detects IgG against nucleoprotein (Abbott SARS-CoV-2 IgG, Abbott Diagnostics, Abbott Park, IL, USA). The incidence rate of KD OPEN 1 Pediatric Infectious Diseases, Shaare-Zedek Medical Center, P.O.B 3235, 91301 Jerusalem, Israel. 2 The Faculty of Medicine, Hebrew University, Jerusalem, Israel. 3 Pediatric Department, Kaplan Medical Center, Rehovot, Israel. 4 Pediatric Department, Shaare-Zedek Medical Center, Jerusalem, Israel. 5 Pediatric Rheumatology Unit, Shaare-Zedek Medical Center, Jerusalem, Israel. 6 The research was performed in full accordance with relevant guidelines and regulations. Informed consent was waived since all patient data were de-identified.

Analysis of variance (ANOVA) was used to determine whether age, temperature, length of stay in the hospital and mean values of the laboratory tests differed between MIS-C, KD or MIS-C/KD patients. Chi-square test was used to compare the categorical variables between the groups. For all analyses, a 2-sided probability < 0.05 was considered statistically significant. To identify independent predictors for MIS-C, logistic regression model was constructed with MIS-C as the dependent variable (MIS-C vs. KD or MIS-C/KD patients). Variables selected by the univariable analyses were included as independent variables. All analyses were done using SPSS version 25.0.

Between February 2020 to October 2020, there were 13 patients with KD, 10 with MIS-C and 5 who met both MIS-C and KD case definitions. The clinical and demographic characteristics of the cohort are presented in Table 1 .

MIS-C patients were predominantly male, aged 5 to 17 years. Eight had positive SARS CoV-2 serology, 3 had positive RT-PCR and all had known exposure to COVID-19. All patients had asymptomatic or mildly symptomatic prior COVID-19 infection. Median time from COVID-19 infection (when known) to presenting with MIS-C and/or KD was 25 days (17-90). One patient without cardiovascular symptoms had severe headache with magnetic resonance imaging (MRI) showing a cytotoxic lesion in the corpus callosum, which was interpreted as a non-specific finding 12 . Most patients (8/10) had acute gastrointestinal (GI) symptoms-all had significant abdominal pain (one had acute abdomen and undergone laparotomy) and 3 with diarrhea. All patients had clinical signs that could resemble those of KD, mainly red eyes and rash (8 and 6 patients, respectively), but none had > 3 clinical KD criteria, and none met the criteria for incomplete KD. Eight of the 10 patients were admitted to the intensive care unit. All received corticosteroid therapy (initially IV methylprednisolone 2 mg/kg/ day) with 3 receiving it in conjunction with IVIG. Overall, 70% (7/10) responded promptly, with defervescence of fever after 1-4 doses of corticosteroids. Three patients had continued fever and inflammation and received pulse methylprednisolone (30 mg/kg/day for 3 days) combined with anakinra. All MIS-C patients were well after median follow up of 29 days (7-105). All were successfully weaned from corticosteroids, had normal acute phase reactants and did not develop coronary artery aneurysms (CAA). KD patients. Seven (54%) patients had complete KD, the rest met the criteria for incomplete KD. None had myocardial involvement or hypotension. All responded to treatment with IVIG, with 4/13 (30%) requiring a second dose. None developed CAA after median follow up of 23 days (8-115).

Five patients met both KD criteria and MIS-C. Of these, 4 had coronary artery dilation and 3 had valvular regurgitation. One 16 year-old patient had all 5 typical clinical KD signs, but also had lymphopenia, thrombocytopenia and excessively elevated troponin. His echo showed left ventricular (LV) dysfunction with no coronary involvement. Of note, he had negative SARS-CoV-2 PCR and serology but resided in an area with a very high incidence of COVID-19. He defervesced after 2 doses of IVIG combined with 2 mg/kg/day of methylprednisolone. A follow-up cardiac MRI demonstrated an area of myocardial scar tissue. Two patients developed uveitis after hospital discharge and required systemic or topical steroids. Over a follow up of 1-2 weeks after discharge, none have developed CAA.

MIS-C vs. KD. Several characteristics differentiated MIS-C patients from those with KD: MIS-C patients were older, were more likely to be hypotensive and have significant GI symptoms, have lymphopenia and thrombocytopenia, and have non-coronary abnormal findings in their echocardiogram (LV dysfunction, valvular regurgitation, pericardial effusion or retrograde aortic diastolic flow). Interestingly, the "intermediate" group of patients, who met both sets of criteria, had intermediate values for most clinical and laboratory variables (Table 1, Fig. S1 ). In multivariate analysis lymphopenia (lymphocyte count < 1500 µL) was an independent predictor of MIS-C, with an adjusted odds ratio of 24 (95% CI 1.3-326, p = 0.02).

KD incidence. The overall rate of KD admissions in 2019 was 4.8 and 1.2 cases/1000 admissions in SZMC and KMC, respectively, compared with 4.7 and 0.9 in 2020 (calculated until the end of October 2020 and adjusted for the decrease in admissions during the lockdown). Seasonality followed data previously reported from Israel 13 (Fig. 1 ).

Our report provides further support from Israeli patients to the new entity of MIS-C, witnessed in many countries, and further characterizes its distinction from the well-defined KD. There is a phenotypic overlap between MIS-C and KD. In particular, considerable similarities exist between MIS-C and KD shock syndrome (KDSS), which is characterized by prominent cardiovascular involvement 2,5 . However, several distinctions help to differentiate these conditions. MIS-C patients were older, had prominent GI symptoms and had lymphopenia and www.nature.com/scientificreports/ thrombocytopenia, which are not common in KDSS. In fact, we found that lymphopenia was an independent predictor of MIS-C. The clinical presentation in our patients is in line with the MIS-C case series reported so far [1] [2] [3] [4] [5] . These reports enrolled patients with positive viral RNA RT-PCR and respiratory symptoms as well as patients with positive serology and/or exposure to COVID-19 patients. Therefore it is possible that some case series represent a mix of patients with acute SARS-CoV-2 infection along with patients with post-infectious inflammation. Furthermore, as COVID-19 becomes endemic in many areas, positive PCR, serology or exposure may merely represent a concurrent phenomenon, and not necessarily explain the clinical presentation. Focusing on the GI and myocardial involvement was recently suggested to be useful in differentiating MIS-C from other "look-alike" clinical entities 14 . Our report adds lymphopenia as a useful simple aid to differentiate between MIS-C and KD. This differentiation is not semantic but has therapeutic and prognostic implications. All of our MIS-C patients responded to corticosteroid therapy with 7/10 responding promptly to standard high dose and 3/10 only after IV pulse methylprednisolone was added. The present guidelines for immunomodulatory treatment in MIS-C are mainly derived from real-life experience and from high-quality data on the treatment of KD 10 . These guidelines recommend IVIG and/or corticosteroids, either alone or in combination, as first-line agents in MIS-C. In KD patients, corticosteroids have a role only as adjunctive therapy to IVIG in certain circumstances indicating a high risk for coronary involvement and/or non-response, or as a rescue therapy (usually after failing to respond to a 2nd dose of IVIG) 15 . Therefore, patients who meet criteria for both KD (usually incomplete) and MIS-C, should be treated with IVIG as first line treatment. A recent retrospective, propensity-score matched study found that MIS-C patients that received combined treatment of IVIG plus methylprednisolone had a better course of fever compared with those treated with IVIG alone 16 .

Further support to the concept of KD and MIS-C as separate entities, is provided by the relatively stable rate of KD cases during 2020 compared with 2019 at our two medical centers. If SARS-CoV-2 was a trigger to KD, we probably would have found an increase in the incidence of KD by now.

Our report represents the experience of two centers, located in regions with high COVID-19 incidence rates. As the COVID-19 epidemic continues to spread, there is an urgent need to improve our understanding of this new disease, particularly developing a more accurate diagnostic criteria that also clearly differentiate this entity from KD. Other multicenter control or "real-life" consensus treatment plan (CTP) studies should focus on determining the optimal treatment modality. 

Hyperinflammatory shock in children during covid-19 pandemic

An outbreak of severe kawasaki-like disease at the italian epicentre of the SARS-COV-2 epidemic: An observational cohort study

Clinical characteristics of 58 children with a pediatric inflammatory multisystem syndrome temporally associated with SARS-COV-2

Multisystem inflammatory syndrome related to covid-19 in previously healthy children and adolescents in New York city

Multisystem inflammatory syndrome in U.S. Children and adolescents

World Health Organization. Multisystem Inflammatory Syndrome in Children and Adolescents with Covid-19: Scientific Brief (WHO, 2020)

Multisystem Inflammatory Syndrome in Children (mis-c) Associated with Coronavirus disease

Multi-inflammatory syndrome in children related to SARS-COV-2 in Spain

Diagnosis, treatment, and long-term management of Kawasaki disease: A scientific statement for health professionals from the American Heart Association

American college of rheumatology clinical guidance for multisystem inflammatory syndrome in children associated with SARS-COV-2 and hyperinflammation in pediatric COVID-19: Version 1

The latent tuberculosis infection cascade of care in Iqaluit

Cytotoxic lesions of the corpus callosum that show restricted diffusion: Mechanisms, causes, and manifestations

Kawasaki disease in Israel

Diagnosing sars-cov-2 related multisystem inflammatory syndrome in children (mis-c): Focus on the gastrointestinal tract and the myocardium

Efficacy of immunoglobulin plus prednisolone for prevention of coronary artery abnormalities in severe Kawasaki disease (raise study): A randomised, open-label, blinded-endpoints trial

Association of intravenous immunoglobulins plus methylprednisolone vs immunoglobulins alone with course of fever in multisystem inflammatory syndrome in children

M.B.M. and O.M. conceptualized the study, supervised the data collection, and analyzed the data. A.G., O.G. and M.G. collected and interpreted data and have critically read the manuscript, A.S. collected data and wrote the first draft, P.H. supervised the data collection and critically read the draft.

The authors declare no competing interests.

The online version contains supplementary material available at https:// doi. org/ 10. 1038/ s41598-021-93389-0.Correspondence and requests for materials should be addressed to M.B.-M.Reprints and permissions information is available at www.nature.com/reprints.Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http:// creat iveco mmons. org/ licen ses/ by/4. 0/.